Medicure Gained 5.71% Yesterday and Double Digits Coming Soon
The last time Medicure (TSXV: MPH) became a 100-bagger in 2013-2016, rising from $0.10 up to $10.67 for a gain of 10,570% in 42 months, its main catalyst was the acquisition of Apicore, an active pharmaceutical ingredients company based in East Windsor, NJ. Medicure borrowed money to acquire Apicore for approximately US$60 million, and successfully sold the business one year later for US$105 million, repaid the debt plus interest and made a total net profit of US$43 million in one year, which is one of the many reasons Medicure is the world’s #1 best managed biotech company.
If Medicure gained by 10,570% from $0.10 up to $10.67 by profiting US$43 million on the acquisition and subsequent sale of a NJ pharmaceutical company, Apicore, in only twelve months… imagine how much MPH will gain over the next twelve months when it profits an estimated US$205 million from the Priority Review Voucher it will receive after MC-1 receives FDA approval.
Not only is Medicure set to make a 4.77x larger amount than what it made a decade ago when it rallied to $10.67 per share, but MPH has significantly less shares outstanding today than it did back then. In 2019, the company repurchased 4 million shares at $6.50 per share at a cost of CAD$26 million. Together with an additional 751,800 shares repurchased in the open market at a cost of CAD$4.15 million, MPH repurchased 4,751,800 shares at a cost of CAD$30.15 million.
This means Medicure is one of the world’s most tightly held stocks. At any time we want, we can begin spreading word about Medicure to biotech investors on social media. There are very few shares available to purchase in the open market between here and $10 per share.
When Medicure made its previous run a decade ago, it did not own Marley Drug, its online telehealth pharmacy platform with 30,000+ customers nationwide and three physical locations in North Carolina, Oregon, and Washington State. It did not yet own ZYPITAMAG, the popular patented drug with growing sales. Medicure did not have any Phase 3 trials taking place like it does today.
Medicure has a 100% chance of making very large gains in the days, weeks, and months ahead. It will be $30 per share by this time next year.
Past performance is not indicative of future results. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. NIA’s President has purchased 87,000 shares of MPH and intends to buy more shares. This communication is for informational and educational purposes only.